Company Pulmatrix Inc Nasdaq
Equities
US74584P1030
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Class of Inhaled Therapeutic Products
100.0
%
| 6 | 100.0 % | 7 | 100.0 % | +20.21% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 6 | 100.0 % | 7 | 100.0 % | +20.21% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Teofilo Raad
CEO | Chief Executive Officer | 54 | 17-05-02 |
Peter Ludlum
DFI | Director of Finance/CFO | 68 | 22-04-17 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Batycky
BRD | Director/Board Member | 56 | 19-10-31 |
Director/Board Member | 54 | 20-06-22 | |
Todd Bazemore
BRD | Director/Board Member | 53 | 20-09-30 |
Anand Varadan
BRD | Director/Board Member | 57 | 21-07-25 |
Teofilo Raad
CEO | Chief Executive Officer | 54 | 17-05-02 |
Michael Higgins
CHM | Chairman | 61 | 15-06-14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,652,285 | 3,652,260 ( 100.00 %) | 0 | 100.00 % |
Company contact information
![address Pulmatrix Inc](https://cdn.zonebourse.com/static/address/23492812.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+16.44% | 122B | |
+18.94% | 114B | |
+19.62% | 25.71B | |
-25.37% | 19.02B | |
-20.21% | 15.83B | |
-20.20% | 15.32B | |
-47.37% | 14.88B | |
+59.91% | 14.82B | |
+4.35% | 14.1B |